Global Anatomic Pathology Testing Market 2017-2021 - Product Image

Global Anatomic Pathology Testing Market 2017-2021

  • ID: 4115349
  • Report
  • Region: Global
  • 95 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • 20/20 GeneSystems
  • Advanced Cell Diagnostics
  • Biocare Medical
  • Danaher
  • Janssen Diagnostic
  • Oxford Cancer Biomarkers
  • MORE
About Anatomic Pathology Testing

The anatomic pathology testing helps in identifying abnormalities in tissue or cell lines and develops personalized care treatment. It helps to evaluate different types of cancers such as lung cancer, breast cancer, colorectal cancer, and chronic conditions such as kidney or liver disease, infectious disease, and autoimmune diseases.

The analysts forecast the global anatomy pathology testing market to grow at a CAGR of 8.26% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global anatomy pathology testing market for 2017-2021. To calculate the market size, the report considers the revenue generated from anatomy pathology testing.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Anatomic Pathology Testing Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- Abbott Diagnostics
- Agilent Technologies
- Danaher
- Roche Diagnostics
- Thermo Fisher Scientific

Other prominent vendors
- 20/20 GeneSystems
- Abcam
- AdnaGen
- Advanced Cell Diagnostics
- Agendia
- Angsana Molecular & Diagnostics Laboratory
- AutoGenomics
- Biocare Medical
- Biocartis
- CellMax Life
- Cancer Genetics
- Digipath
- Enzo Biochem
- Epic Sciences
- Janssen Diagnostic
- Monogram Biosciences
- Nucleix
- Omnyx
- Oxford Cancer Biomarkers
- RareCyte
- SAKURA FINETEK USA
- Tecan
- VolitionRx

Market drivers
- Growing prevalence of cancer in demographics
- For a full, detailed list, view the full report

Market challenges
- High initial investment and maintenance costs
- For a full, detailed list, view the full report

Market trends
- Presence of venture capitalists in market
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 20/20 GeneSystems
  • Advanced Cell Diagnostics
  • Biocare Medical
  • Danaher
  • Janssen Diagnostic
  • Oxford Cancer Biomarkers
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 06: Market segmentation by products

Instruments and imaging systems

Consumables and accessories

PART 07: Market segmentation by application

Breast cancer

Lung cancer

Colorectal cancer

Lymphoma

Cervical cancer

Prostate cancer

Other diseases

PART 08: Market segmentation by end-user

Hospitals

Clinical diagnostic laboratories

Physicians€™ office laboratories

PART 09: Geographical segmentation

Anatomic pathology testing market in Americas

Anatomic pathology testing market in EMEA

Anatomic pathology testing market in APAC

PART 10: Market drivers

Growing prevalence of cancer in demographics

Use of biomarkers for disease diagnosis and increasing efficiency

Paradigm shift toward precision diagnosis through personalized medicine

PART 11: Impact of drivers

PART 12: Market challenges

Insurance coverage and reimbursement issues

Limitations of closed systems

High initial investment and maintenance cost

PART 13: Impact of drivers and challenges

PART 14: Market trends

Presence of venture capitalists in market

Ready-to-use reagents

Business strategies to increase market competitiveness

PART 15: Vendor landscape

Competitive landscape analysis

PART 16: Key vendor analysis

Abbott Diagnostics

Agilent Technologies

Danaher

Roche Diagnostics

Thermo Fisher Scientific

Other prominent vendors

PART 17: Appendix

List of abbreviations

PART 18: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Methods used in anatomic pathology testing
Exhibit 03: Use of digital pathology testing
Exhibit 04: Global anatomic pathology testing market 2016-2021 ($ millions)
Exhibit 05: Product dynamic analysis of instruments and reagents in 2016 and 2021
Exhibit 06: Five forces analysis
Exhibit 07: Global anatomic pathology testing market by products in 2016 and 2021 ($ billions)
Exhibit 08: Market overview: Instruments and imaging systems
Exhibit 09: Anatomic pathology testing market by instruments and imaging systems 2016-2021 ($ billions)
Exhibit 10: Market overview: Consumables and accessories
Exhibit 11: Anatomic pathology testing market by consumables and accessories 2016-2021 ($millions)
Exhibit 12: Global anatomic pathology testing market by application in 2016
Exhibit 13: Global anatomic pathology testing market by end-users in 2015
Exhibit 14: Strategies, benefits and challenges of clinical diagnostic laboratories to remain competitive
Exhibit 15: Global anatomic pathology testing market by geography in 2016 and 2021 ($billions)
Exhibit 16: Market overview: Anatomic pathology testing market in Americas
Exhibit 17: Anatomic pathology testing market in Americas 2016-2021 ($ billions)
Exhibit 18: Key takeaway: Anatomic pathology testing market in US
Exhibit 19: PEST analysis: Anatomic pathology testing market in UK
Exhibit 20: Market overview: Anatomic pathology testing market in EMEA
Exhibit 21: Anatomic pathology testing market in EMEA 2016-2021 ($billions)
Exhibit 22: Key takeaway: Anatomic pathology testing market in UK
Exhibit 23: PEST analysis: Anatomic pathology testing market in UK
Exhibit 24: Market overview: Anatomic pathology testing market in APAC
Exhibit 25: Anatomic pathology testing market in APAC 2016-2021 ($billions)
Exhibit 26: Key takeaway: Anatomic pathology testing market in China
Exhibit 27: PEST analysis: Anatomic pathology testing market in China
Exhibit 28: People in age group 60 years and above worldwide 2010-2050
Exhibit 29: Companies and laboratories focusing on biomarkers
Exhibit 30: Companies focusing on companion diagnostic and personalized medicine
Exhibit 31: Impact of drivers
Exhibit 32: Impact of drivers and challenges
Exhibit 33: Partnership between companies and venture capitalists
Exhibit 34: Business strategies by companies to remain competitive in market
Exhibit 35: Competitive structure analysis of global anatomic pathology testing market 2015
Exhibit 36: Competitive analysis of global anatomic pathology testing market 2016
Exhibit 37: Abbott Diagnostics: Strength assessment
Exhibit 38: Abbott Diagnostics: Strategy assessment
Exhibit 39: Abbott Diagnostics: Opportunity assessment
Exhibit 40: Agilent Technologies: Strength assessment
Exhibit 41: Agilent Technologies: Strategy assessment
Exhibit 42: Agilent Technologies: Opportunity assessment
Exhibit 43: Danaher: Strength assessment
Exhibit 44: Danaher: Strategy assessment
Exhibit 45: Danaher: Opportunity assessment
Exhibit 46: Roche Diagnostics: Strength assessment
Exhibit 47: Roche Diagnostics: Strategy assessment
Exhibit 48: Roche Diagnostics: Opportunity assessment
Exhibit 49: Thermo Fisher Scientific: Strength assessment
Exhibit 50: Thermo Fisher Scientific: Strategy assessment
Exhibit 51: Thermo Fisher Scientific: Opportunity assessment
Exhibit 52: Other prominent vendors
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 20/20 GeneSystems
  • Advanced Cell Diagnostics
  • Biocare Medical
  • Danaher
  • Janssen Diagnostic
  • Oxford Cancer Biomarkers
  • MORE
New Report Released: – Global Anatomic Pathology Testing Market 2017-2021

The author of the report recognizes the following companies as the key players in the global anatomy pathology testing market: Abbott Diagnostics, Agilent Technologies, Danaher, Roche Diagnostics, and Thermo Fisher Scientific

Other Prominent Vendors in the market are: 20/20 GeneSystems, Abcam, AdnaGen, Advanced Cell Diagnostics, Agendia, Angsana Molecular & Diagnostics Laboratory, AutoGenomics, Biocare Medical, Biocartis, CellMax Life, Cancer Genetics, Digipath, Enzo Biochem, Epic Sciences, Janssen Diagnostic, Monogram Biosciences, Nucleix, Omnyx, Oxford Cancer Biomarkers, RareCyte, SAKURA FINETEK USA, Tecan, and VolitionRx

Commenting on the report, an analyst from the research team said: “The small companies and new players in the market approach venture capitalists to develop anatomic pathology testing products. These capitalists have realized the significant potential these companies have to develop innovative technologies and products in the area of immunohistochemistry and cytology for diagnosis of chronic diseases such as cancer. This has increased the financial flow support from venture capitalists, which is accelerating the development of anatomic pathology testing market. Post registration and market approval, venture capitalists take a share from the total revenue generated by these companies.”

According to the report, the personalized medicine is “individualized” to treat chronic diseases. Since each individual has unique pathology and physiology; to customize the treatment plan, personalized medicines are used. In such cases, the proteins and genes in cells of tissues, which control various functions of the body are tested. A defect in a particular protein or gene structure can result in specific conditions and disorders. Anatomic pathology helps to understand the cellular framework of the individual, which is important for developing a personalized treatment. The development of personalized medicine depends on the identification and study of these defective proteins and genes extracted from tissues.

Further, the report states that the anatomic pathology testing instruments with advanced features, such as automation and inbuilt scanners, are expensive to procure and maintain. The upkeep of automated microscopes, high-resolution digital cameras, and monitors for anatomic pathology sample analysis that need to comply with strict standards and regulations is also expensive. In addition, the big data obtained from bio sample analysis require more storage. The system integration to prevent cross-contamination between samples for comprehensive reporting through advanced image analysis algorithms also increases the overall cost of the technology. The anatomic pathology testing instruments and imaging systems employ sophisticated techniques and require skilled engineers for their maintenance and operation. All these factors increase the costs associated with the purchase and maintenance of instruments, which will negatively influence the market growth.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Abbott Diagnostics
  • Agilent Technologies
  • Danaher
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • 20/20 GeneSystems
  • Abcam
  • AdnaGen
  • Advanced Cell Diagnostics
  • Agendia
  • Angsana Molecular & Diagnostics Laboratory
  • AutoGenomics
  • Biocare Medical
  • Biocartis
  • CellMax Life
  • Cancer Genetics
  • Digipath
  • Enzo Biochem
  • Epic Sciences
  • Janssen Diagnostic
  • Monogram Biosciences
  • Nucleix
  • Omnyx
  • Oxford Cancer Biomarkers
  • RareCyte
  • SAKURA FINETEK USA
  • Tecan
  • VolitionRx
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll